Last reviewed · How we verify
ProAir Digihaler
ProAir Digihaler is a digital inhaler device that delivers albuterol (salbutamol) to relieve acute bronchospasm and airway obstruction in asthma and COPD patients.
ProAir Digihaler is a digital inhaler device that delivers albuterol (salbutamol) to relieve acute bronchospasm and airway obstruction in asthma and COPD patients. Used for Acute relief of bronchospasm in asthma, Acute relief of bronchospasm in chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | ProAir Digihaler |
|---|---|
| Also known as | Digihaler Device |
| Sponsor | Pulmonary Research Institute of Southeast Michigan |
| Drug class | Short-acting beta-2 agonist (SABA) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
ProAir Digihaler is a metered-dose inhaler (MDI) containing albuterol, a short-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing rapid bronchodilation. The device incorporates digital connectivity to track inhaler use, provide feedback on proper technique, and monitor medication adherence. This combination of a proven bronchodilator with digital health monitoring aims to improve patient outcomes and medication compliance.
Approved indications
- Acute relief of bronchospasm in asthma
- Acute relief of bronchospasm in chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Nervousness
- Palpitations
- Tachycardia
Key clinical trials
- Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (PHASE3)
- Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype (EARLY_PHASE1)
- Teva Asthma Predictive Analytics Study (PHASE4)
- ProAir Digihaler in COPD Disease Management: A Real World Study
- Secondhand Smoke Respiratory Health Study (PHASE4)
- Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma (NA)
- The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ProAir Digihaler CI brief — competitive landscape report
- ProAir Digihaler updates RSS · CI watch RSS
- Pulmonary Research Institute of Southeast Michigan portfolio CI